<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-seven patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> in relapse were treated with a three-drug combination that included a 3- or 4-day course of AMSA with total doses ranging from 600 mg/m2 to 740 mg/m2 I.V., <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> 25 mg/m2 I.V. followed by 200 mg/m2 by continuous infusion daily for 5 days, and thioguanine 100 mg/m2 p.o. q 12h for 5 days </plain></SENT>
<SENT sid="1" pm="."><plain>Eight of the 25 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> achieved a complete remission and 3 a partial remission </plain></SENT>
<SENT sid="2" pm="."><plain>None of the five patients with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> achieved a response and there was one partial remission in the seven patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or blastic <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Reversible toxicity included <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo> (78%), <z:hpo ids='HP_0001596'>alopecia</z:hpo> (100%), <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> (100%), mild <z:hpo ids='HP_0010280'>stomatitis</z:hpo> (63%), and hepatic dysfunction (24%) </plain></SENT>
<SENT sid="4" pm="."><plain>One patient developed <z:hpo ids='HP_0001250'>seizures</z:hpo> and <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The activity of this combination in heavily treated patients with ANLL is comparable to that of the <z:chebi fb="0" ids="48120">anthracycline</z:chebi>-containing regimens, and its use in previously untreated patients with ANLL should now be explored </plain></SENT>
</text></document>